These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8918930)

  • 1. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
    Firestone CY; Whitehead SS; Collins PL; Murphy BR; Crowe JE
    Virology; 1996 Nov; 225(2):419-22. PubMed ID: 8918930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.
    Crowe JE; Bui PT; Davis AR; Chanock RM; Murphy BR
    Vaccine; 1994 Jul; 12(9):783-90. PubMed ID: 7975856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.
    Crowe JE; Bui PT; Siber GR; Elkins WR; Chanock RM; Murphy BR
    Vaccine; 1995 Jun; 13(9):847-55. PubMed ID: 7483808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.
    Crowe JE; Bui PT; London WT; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1994 Jun; 12(8):691-9. PubMed ID: 8091846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.
    Connors M; Crowe JE; Firestone CY; Murphy BR; Collins PL
    Virology; 1995 Apr; 208(2):478-84. PubMed ID: 7747420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.
    Juhasz K; Whitehead SS; Boulanger CA; Firestone CY; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(11-12):1416-24. PubMed ID: 10195777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.
    Crowe JE; Firestone CY; Whitehead SS; Collins PL; Murphy BR
    Virus Genes; 1996; 13(3):269-73. PubMed ID: 9035372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
    Whitehead SS; Firestone CY; Collins PL; Murphy BR
    Virology; 1998 Aug; 247(2):232-9. PubMed ID: 9705916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
    Whitehead SS; Firestone CY; Karron RA; Crowe JE; Elkins WR; Collins PL; Murphy BR
    J Virol; 1999 Feb; 73(2):871-7. PubMed ID: 9882287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.
    Juhasz K; Whitehead SS; Bui PT; Biggs JM; Crowe JE; Boulanger CA; Collins PL; Murphy BR
    J Virol; 1997 Aug; 71(8):5814-9. PubMed ID: 9223470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo.
    Crowe JE; Randolph V; Murphy BR
    Virus Res; 1999 Jan; 59(1):13-22. PubMed ID: 10854162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.
    Luongo C; Winter CC; Collins PL; Buchholz UJ
    J Virol; 2012 Oct; 86(19):10792-804. PubMed ID: 22837193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
    Whitehead SS; Hill MG; Firestone CY; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 1999 Dec; 73(12):9773-80. PubMed ID: 10559287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
    Crowe JE; Collins PL; London WT; Chanock RM; Murphy BR
    Vaccine; 1993 Nov; 11(14):1395-404. PubMed ID: 8310760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Safety and Immune Efficacy of Recombinant Human Respiratory Syncytial Virus Strain Long Live Attenuated Vaccine Candidates.
    Wang LN; Peng XL; Xu M; Zheng YB; Jiao YY; Yu JM; Fu YH; Zheng YP; Zhu WY; Dong ZJ; He JS
    Virol Sin; 2021 Aug; 36(4):706-720. PubMed ID: 33559831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
    Wright PF; Karron RA; Belshe RB; Thompson J; Crowe JE; Boyce TG; Halburnt LL; Reed GW; Whitehead SS; Anderson EL; Wittek AE; Casey R; Eichelberger M; Thumar B; Randolph VB; Udem SA; Chanock RM; Murphy BR
    J Infect Dis; 2000 Nov; 182(5):1331-42. PubMed ID: 11010838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
    Nelson CL; Tang RS; Stillman EA
    Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030ΔSH) at permissive and non-permissive temperatures.
    Schickli JH; Kaur J; Tang RS
    Virus Res; 2012 Oct; 169(1):38-47. PubMed ID: 22771939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus.
    Hsu KH; Crowe JE; Lubeck MD; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1995 Apr; 13(5):509-15. PubMed ID: 7543716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.